Polaryx Therapeutics, Inc. (PLYX) Financial Statements

23 Followers

Polaryx Therapeutics, Inc. Financial Overview

Polaryx Therapeutics, Inc.'s market cap is currently $100.19M. The company's EPS TTM is $-0.1217; its P/E ratio is -16.52; Polaryx Therapeutics, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00
Operating Income	$ -7.82M	$ -4.35M	$ -3.78M
EBITDA	$ -8.98M	$ -30.36M	$ -3.78M
Net Income	$ -8.98M	$ -30.36M	$ -3.78M
Balance Sheet
Cash & Short-Term Investments	$ 5.14M	$ 4.62M	$ 2.00K
Total Assets	$ 5.42M	$ 5.00M	$ 2.31M
Total Debt	$ 0.00	$ 0.00	$ 128.00K
Net Debt	$ -5.14M	$ -4.62M	$ 126.00K
Total Liabilities	$ 855.00K	$ 289.00K	$ 1.04M
Stockholders' Equity	$ 4.57M	$ 4.71M	$ 1.28M
Cash Flow
Free Cash Flow	$ -3.94M	$ -2.57M	$ -173.00K
Operating Cash Flow	$ -3.94M	$ -2.57M	$ -173.00K
Investing Cash Flow	$ 0.00	$ 0.00	$ 0.00
Financing Cash Flow	$ 4.47M	$ 7.19M	$ 128.00K

Currency in USD

Polaryx Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Polaryx Therapeutics, Inc. Debt to Assets

Balance Sheet >

Polaryx Therapeutics, Inc. Cash Flow

Cash Flow >

Polaryx Therapeutics, Inc. Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >